Sugi Predict

Sugi Predict / Compounds / SCHEMBL9922798

SCHEMBL9922798

SCHEMBL9922798

NC(CCCCNC(=O)CCS)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OTC P00480 1/20 0.54
▸ NOD1 Q9Y239 3/20 0.49
▸ GSR P00390 2/20 0.47
▸ TDP1 Q9NUW8 1/20 0.46
▸ HDAC3 O15379 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC10 Q969S8 1/20 0.46
▸ HDAC11 Q96DB2 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46
▸ HDAC9 Q9UKV0 1/20 0.46
▸ HDAC5 Q9UQL6 1/20 0.46
▸ ARG2 P78540 4/20 0.43
▸ ARG1 P05089 3/20 0.43
▸ PTGS1 P23219 1/20 0.41
▸ GSTK1 Q9Y2Q3 1/20 0.41
▸ GRM8 O00222 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18643429 1.00 OTC (0.54) OTCNOD1GSRTDP1HDAC3
SCHEMBL12801715 1.00 OTC (0.54) OTCNOD1GSRTDP1HDAC3
SCHEMBL18656205 0.95 OTC (0.59) OTCNOD1GSRTDP1HDAC3
SCHEMBL4480340 0.92 OTC (0.53) OTCNOD1GSRTDP1HDAC3
SCHEMBL19733064 0.92 OTC (0.53) OTCNOD1GSRTDP1HDAC3
SCHEMBL29486962 0.88 OTC (0.58) OTCNOD1GSRTDP1ARG2
SCHEMBL10005285 0.88 OTC (0.58) OTCNOD1GSRTDP1ARG2
SCHEMBL365299 0.88 OTC (0.58) OTCNOD1GSRTDP1ARG2
SCHEMBL16221672 0.85 DPP7 (0.42) OTCNOD1TDP1HDAC3HDAC4
SCHEMBL41534 0.85 NOD1 (0.49) OTCNOD1GSRTDP1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780935-B2 Mutant antibodies and conjugation thereof PFIZER HEALTHCARE IRELAND (IE) 2023-10-10 — — US disclosed
US-11780935-B2 Mutant antibodies and conjugation thereof PFIZER HEALTHCARE IRELAND (IE) 2023-10-10 — — US disclosed
US-20210147576-A1 MUTANT ANTIBODIES AND CONJUGATION THEREOF PFIZER HEALTHCARE IRELAND (IE) 2021-05-20 — — US disclosed
US-9163227-B2 Anti-diabetic compounds COVX TECHNOLOGIES IRELAND LIMITED (IE) 2015-10-20 — — US disclosed
US-8741291-B2 Multifunctional antibody conjugates COVX TECHNOLOGIES IRELAND, LIMITED (IE) 2014-06-03 — — US disclosed
US-8741291-B2 Multifunctional antibody conjugates COVX TECHNOLOGIES IRELAND, LIMITED (IE) 2014-06-03 — — US disclosed
WO-2013105013-A1 MUTANT ANTIBODIES AND CONJUGATION THEREOF COVX TECHNOLOGIES IRELAND LIMITED (IE) 2013-07-18 — — WO disclosed
WO-2013093720-A2 ANTI-DIABETIC COMPOUNDS PFIZER INC. (US) 2013-06-27 — — WO disclosed
US-20130164310-A1 ANTI-DIABETIC COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED 2013-06-27 — — US disclosed
US-20120201809-A1 MULTIFUNCTIONAL ANTIBODY CONJUGATES COVX TECHNOLOGIES IRELAND, LIMITED (IE) 2012-08-09 — — US disclosed
US-20120201809-A1 MULTIFUNCTIONAL ANTIBODY CONJUGATES COVX TECHNOLOGIES IRELAND, LIMITED (IE) 2012-08-09 — — US disclosed
US-20120148586-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS CHOU JOYCE CHING TSU (US) 2012-06-14 — — US disclosed
WO-2012007896-A1 MULTIFUNCTIONAL ANTIBODY CONJUGATES COVX TECHNOLOGIES IRELAND, LTD. (IE) 2012-01-19 — — WO disclosed
WO-2011024110-A2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS RINAT NEUROSCIENCE CORPORATION (US) 2011-03-03 — — WO disclosed
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED (IE) 2009-04-16 — — US disclosed
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED (IE) 2009-04-16 — — US disclosed
US-20090042745-A1 BIOSENSOR CHIP FUJIFILM CORPORATION (JP) 2009-02-12 — — US disclosed
WO-2008081418-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED (IE) 2008-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147576-A1 MUTANT ANTIBODIES AND CONJUGATION THEREOF IGLV6-57, IGSF11, F13B OTC 4241/4885NOD1 2434/4885GSR 2375/4885
US-11780935-B2 Mutant antibodies and conjugation thereof IGLV6-57, IGSF11, F13B OTC 4243/4885NOD1 2408/4885GSR 2412/4885
US-20120148586-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS GLP1R, GCGR, GIPR OTC 4608/4885NOD1 238/4885GSR 1258/4885
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS GLP1R, GIPR, GCGR OTC 4655/4885NOD1 367/4885GSR 761/4885
US-20120201809-A1 MULTIFUNCTIONAL ANTIBODY CONJUGATES CLTB, CLTA, FCGRT OTC 4819/4885NOD1 1926/4885GSR 4717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.